Proprotein convertase subtilisin/kexin type 9: A new target molecule for gene therapy

• Autorzy: Banaszewska A. , Piechota M. , Plewa R.
• Języki publikacji: EN

Abstrakty

EN

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel target for controlling plasma levels of low-density lipoprotein cholesterol (LDL-C) and decreasing the risk of cardiovascular diseases. At present it is clear that the major classes of commonly prescribed lipid-lowering medications increase serum PCSK9 levels and fail to protect a significant percentage of patients from cardiovascular events. Therefore development of new LDL-C lowering medications that either do not increase circulating PCSK9 levels or work through inhibition of PCSK9 expression and protease activity is a highly desirable approach to overcome hypercholesterolemia. Since there are several agents which are being evaluated in human preclinical and clinical trials, this review summarizes current therapeutic strategies targeting PCSK9, including specific antibodies, antisense oligonucleotides, small interfering RNAs (siRNAs) and other small-molecule inhibitors.

Słowa kluczowe

EN

proprotein convertase subtilisin kexin type 9; new target molecule; gene therapy; subtilisin treatment; cholesterol; LDL cholesterol; receptor degradation; statin; fibrate; antibody; antisense oligonucleotide; hypercholesterolemia

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2012
• Tom: 17
• Numer: 2
• Opis fizyczny: p.228-239,ref.

Twórcy

autor

Banaszewska A.

• Department of Animal Physiology and Development, Adam Mickiewicz University, 89 Umultowska St., 61-614 Poznan, Poland

autor

Piechota M.

autor

Plewa R.

Bibliografia

• 1. Abifadel, M., Varret, M., Rabès, J.P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J.M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N.G. and Boileau, C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34 (2003) 154-156.
• 2. Cohen, J.C., Boerwinkle, E., Mosley, T.H. Jr. and Hobbs, H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 23 (2006) 1264-1272.
• 3. Rashid, S., Curtis, D.E., Garuti, R., Anderson, N.N., Bashmakov, Y., Ho, Y.K., Hammer, R.E., Moon, Y.A. and Horton, J.D. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. USA 12 (2005) 5374-5379.
• 4. Zhao, Z., Tuakli-Wosornu, Y., Lagace, T.A., Kinch, L., Grishin, N.V., Horton, J.D., Cohen, J.C. and Hobbs, H.H. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79 (2006) 514-523.
• 5. Hooper, A.J., Marais, A.D., Tanyanyiwa, D.M. and Burnett, J.R. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 193 (2007) 445-448.
• 6. Cariou, B., Ouguerram, K., Zaïr, Y., Guerois, R., Langhi, C., Kourimate, S., Benoit, I., Le May, C., Gayet, C., Belabbas, K., Dufernez, F., Chétiveaux, M., Tarugi, P., Krempf, M., Benlian, P. and Costet, P. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler. Thromb. Vasc. Biol. 29 (2009) 2191-2197.
• 7. Kozłowski, D., Sominka, D., Kogut-Dębska, K. and Raczak, G. Statin use in the treatment of metabolic patient. Geriatria 2 (2008) 231-236.
• 8. Dubuc, G., Chamberland, A., Wassef, H., Davignon, J., Seidah, N.G., Bernier, L. and Prat, A. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1454-1459.
• 9. Careskey, H.E., Davis, R.A., Alborn, W.E., Troutt, J.S., Cao, G. and Konrad, R.J. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J. Lipid Res. 49 (2008) 394-398.
• 10. Costet, P., Hoffmann, M.M., Cariou, B., Guyomarc'h Delasalle, B., Konrad, T. and Winkler, K. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 212 (2010) 246-251.
• 11. Welder, G., Zineh, I., Pacanowski, M.A., Troutt, J.S., Cao, G. and Konrad, R.J. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J. Lipid Res. 51 (2010).
• 12. Grundy, S.M., Vega, G.L., Yuan, Z., Battisti, W.P., Brady, W.E. and Palmisano, J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am. J. Cardiol. 95 (2005) 462-468.
• 13. Keating, G.M. and Croom K.F. Fenofibrate. A review of its use in primary dyslipidemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 67 (2007) 121-153.
• 14. Kourimate, S., Le, M.C., Langhi, C., Jarnoux, A.L., Ouguerram, K., Zair, Y., Nguyen, P., Krempf, M., Cariou, B. and Costet, P. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. J. Biol. Chem. 283 (2008) 9666-9673.
• 15. Lambert, G., Jarnoux, A.L., Pineau, T., Pape, O., Chetiveaux, M., Laboisse, C., Krempf, M. and Costet, P. Fasting induces hyperlipidemia in mice overexpressing PCSK9: Lack of modulation of VLDL hepatic output by the LDLr. Endocrinology 22 (2006) 4985-4995.
• 16. Troutt, J.S., Alborn, W.E., Cao, G. and Konrad, R.J. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J. Lipid Res. 51 (2010) 345-351.
• 17. Lambert G, Ancellin N, Charlton F, Comas, D., Pilot, J., Keech, A., Patel, S., Sullivan, D.R., Cohn, J.S., Rye, K.A. and Barter, P.J. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin. Chem. 54 (2008) 1038-1045.
• 18. Mayne, J., Dewpura, T., Raymond, A., Cousins, M., Chaplin, A., Lahey, K.A., Lahaye, S.A., Mbikay, M., Ooi, T.C. and Chrétien, M. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health. Dis. 11 (2008) 7-22.
• 19. Jeu, L. and Cheng, J.W. Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clin. Ther. 25 (2003) 2352-2387.
• 20. Dubuc, G., Tremblay, M., Pare, G., Jacques, H., Hamelin, J., Benjannet, S., Boulet, L., Genest, J., Bernier, L., Seidah, N.G. and Davignon, J. A new method for measurement of total plasma PCSK9: clinical applications. J. Lipid Res. 51 (2010) 140-149.
• 21. Davignon, J. and Dubuc, G. Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Trans. Am. Clin. Climatol. Assoc. 120 (2009) 163-173.
• 22. Ason, B., Tep, S., Davis, H.R. Jr., Xu, Y., Tetzloff, G., Galinski, B., Soriano, F., Dubinina, N., Zhu, L., Stefanni, A., Wong, K.K., Tadin-Strapps, M., Bartz, S.R., Hubbard, B., Ranalletta, M., Sachs, A.B., Flanagan, W.M., Strack, A. and Kuklin, N.A. Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. J. Lipid Res. 52 (2011) 679-687.
• 23. Gouni-Berthold, I., Berthold, H.K., Gylling, H., Hallikainen, M., Giannakidou, E., Stier, S., Ko, Y., Patel, D., Soutar, A.K., Seedorf, U., Mantzoros, C.S., Plat, J. and Krone, W. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis 198 (2008) 198-207.
• 24. Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., Wang, S., Wu, J., Wang, Y., Li, Z., Liu, J. and Jiang, J.D. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med. 10 (2004) 1344-1351.
• 25. Cameron, J., Ranheim, T., Kulseth, M.A., Leren, T.P. and Berge, K.E. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis 201 (2008) 266-273.
• 26. Li, H., Dong, B., Park, S.W., Lee, H.S., Chen, W. and Liu, J. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J. Biol. Chem. 284 (2009) 28885-28895.
• 27. Shan, L., Pang, L., Zhang, R., Murgolo, N.J., Lan, H. and Hedrick, J.A. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem. Biophys. Res. Commun. 10 (2008) 69-73.
• 28. Ni, Y.G., Di Marco, S., Condra J.H., Peterson, L.B., Wang, W., Wang, F., Pandit, S., Hammond, H.A., Rosa, R., Cummings, R.T., Wood, D.D., Liu, X., Bottomley, M.J., Shen, X., Cubbon, R.M., Wang, S.P., Johns, D.G., Volpari, C., Hamuro, L., Chin, J., Huang, L., Zhao, J.Z., Vitelli, S., Haytko, P., Wisniewski, D., Mitnaul, L.J., Sparrow, C.P., Hubbard, B., Carfí, A. and Sitlani, A. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J. Lipid Res. 52 (2011) 78-86.
• 29. Chan, J.C., Piper, D.E., Cao, Q., Liu, D., King, C., Wang, W., Tang, J., Liu, Q., Higbee, J., Xia, Z., Di, Y., Shetterly, S., Arimura, Z., Salomonis, H., Romanow, W.G., Thibault, S.T., Zhang, R., Cao, P., Yang, X.P., Yu, T., Lu, M., Retter, M.W., Kwon, G., Henne, K., Pan, O., Tsai, M.M., Fuchslocher, B., Yang, E., Zhou, L., Lee, K.J., Daris, M., Sheng, J., Wang, Y., Shen, W.D., Yeh, W.C., Emery, M., Walker, N.P., Shan, B., Schwarz, M. and Jackson, S.M. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl. Acad. Sci. USA 16 (2009) 9820-9825.
• 30. Information obtained from the web page: http://clinicaltrials.gov/ct2/show/NCT01375751?term=amg+145+phase+2& rank=3
• 31. Information obtained from the web page http://clinicaltrials.gov/ct2/show/NCT01163851?term=RN316&rank=2
• 32. Citi Investment Research Global Healthcare Conference, New York 2010.
• 33. Information obtained from the web page http://clinicaltrials.gov/ct2/show/NCT01266876?term=REGN727+phase+2 &rank=3
• 34. Graham, M.J., Lemonidis, K.M., Whipple, C.P., Subramaniam, A., Monia, B.P., Crooke, S.T. and Crooke, R.M. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J. Lipid Res. 48 (2007) 763-767.
• 35. Gupta, N., Fisker, N., Asselin, M.C., Lindholm, M., Rosenbohm, C., Ørum, H., Elmén, J., Seidah, N.G. and Straarup, E.M. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One 17 (2010) e10682. DOI: 10.1371/journal.pone. 0010682.
• 36. PCSK9 Conference, Locked Nucleic Acid antisense oligonucleotide inhibition of PCSK9, March 11, 2010. Information obtained from the web page http://www.santaris.com/news/2011/05/04/santaris-pharma-advancesnew-cholesterol-lowering-drug-spc5001-inhibiting-exciting-n
• 37. Information obtained from the web page http://clinicaltrials.gov/ct2/show/NCT01350960?term=SPC5001&rank=1
• 38. Dykxhoorn, D.M., Novina, C.D. and Sharp, P.A. Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell. Biol. 4 (2003) 457-467.
• 39. Frank-Kamenetsky, M., Grefhorst, A., Anderson, N.N., Racie, T.S., Bramlage, B., Akinc, A., Butler, D., Charisse, K., Dorkin, R., Fan, Y., Gamba-Vitalo, C., Hadwiger, P., Jayaraman, M., John, M., Jayaprakash, K.N., Maier, M., Nechev, L., Rajeev, K.G., Read, T., Röhl, I., Soutschek, J., Tan, P., Wong, J., Wang, G., Zimmermann, T., de Fougerolles, A., Vornlocher, HP., Langer, R., Anderson, D.G., Manoharan, M., Koteliansky, V., Horton, J.D. and Fitzgerald, K. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl. Acad. Sci. USA 19 (2008) 11915-119120.
• 40. RNAi for Target Validation and as a Therapeutic, Keystone Symposium, Colorado 2007.